As the CD47/SIRPα cancer cell/Mφ axis is commonly expressed in NSCLC a therapeutic blockage could prove useful as adjuvant or neo-adjuvant immunotherapy in operable NSCLC [21]. This evidence concerns the gene SIRPA and non-small cell lung carcinoma.